RADIANCE-HTN CLINICAL TRIAL
RADIANCE-HTN is a multicenter, blinded, randomized (1:1), sham-controlled trial to evaluate the use of the Paradise Ultrasound Renal Denervation System to reduce ambulatory blood pressure in patients with mild-moderate hypertension (SOLO Cohort) and resistant hypertension (TRIO Cohort). Both cohorts were individually powered for efficacy with a primary endpoint of daytime systolic ambulatory blood pressure (ABP) at 2 months (2M).
The study was conducted at over 50 centers in 7 countries (United States, United Kingdom, France, Germany, Netherlands, Belgium, and Poland), and 282 subjects were randomized.